Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA-CAG in Newly Diagnosed AML
NCT05662956Phase 2Completed
- Sponsor
- Hematology Department, 920th Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Hematology Department, 920th Hospital. Started Dec 2022; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05662956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662956.